Ademetionine
Alternative Names: MSI-190; MSI-195; S-Adenosyl-L-Methionine; Sam-E; SAMe; StradaLatest Information Update: 30 Oct 2021
At a glance
- Originator MSI Methylation Sciences
- Class Amino acids; Antidepressants; Nootropics
- Mechanism of Action Beta adrenergic receptor modulators; Biogenic monoamine uptake modulators; Cytokine modulators; Muscarinic receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Major depressive disorder
Most Recent Events
- 09 Jun 2017 Ademetionine is still at phase II development stage for Major depressive disorder in USA (PO) (MSI Methylation Sciences website, June 2017)
- 06 Sep 2016 MSI Methylation Sciences plans a pivotal phase III programme for Major depressive disorder (Adjunctive treatment) in USA, European Union and Japan (MSI Methylation Sciences pipeline, September 2016)
- 27 Jan 2016 Efficacy and adverse events data from the phase II trial in Major depressive disorder released by MSI Methylation Sciences